Impact of RBMS 3 Progression on Expression of EMT Markers
Tomasz Górnicki,
Jakub Lambrinow,
Monika Mrozowska,
Klaudia Krawczyńska,
Natalia Staszko,
Alicja Kmiecik,
Aleksandra Piotrowska,
Agnieszka Gomułkiewicz,
Hanna Romanowicz,
Beata Smolarz,
Marzena Podhorska-Okołów,
Jędrzej Grzegrzółka,
Agnieszka Rusak,
Piotr Dzięgiel
Affiliations
Tomasz Górnicki
Division of Histology and Embryology, Department of Human Morphology and Embryology, Wroclaw Medical University, T. Chalubinskiego 6a St., 50-368 Wroclaw, Poland
Jakub Lambrinow
Division of Histology and Embryology, Department of Human Morphology and Embryology, Wroclaw Medical University, T. Chalubinskiego 6a St., 50-368 Wroclaw, Poland
Monika Mrozowska
Division of Histology and Embryology, Department of Human Morphology and Embryology, Wroclaw Medical University, T. Chalubinskiego 6a St., 50-368 Wroclaw, Poland
Klaudia Krawczyńska
Division of Histology and Embryology, Department of Human Morphology and Embryology, Wroclaw Medical University, T. Chalubinskiego 6a St., 50-368 Wroclaw, Poland
Natalia Staszko
Division of Histology and Embryology, Department of Human Morphology and Embryology, Wroclaw Medical University, T. Chalubinskiego 6a St., 50-368 Wroclaw, Poland
Alicja Kmiecik
Division of Histology and Embryology, Department of Human Morphology and Embryology, Wroclaw Medical University, T. Chalubinskiego 6a St., 50-368 Wroclaw, Poland
Aleksandra Piotrowska
Division of Histology and Embryology, Department of Human Morphology and Embryology, Wroclaw Medical University, T. Chalubinskiego 6a St., 50-368 Wroclaw, Poland
Agnieszka Gomułkiewicz
Division of Histology and Embryology, Department of Human Morphology and Embryology, Wroclaw Medical University, T. Chalubinskiego 6a St., 50-368 Wroclaw, Poland
Hanna Romanowicz
Laboratory of Cancer Genetics, Department of Pathology, Polish Mother’s Memorial Hospital Research Institute, Rzgowska 281/289, 93-338 Lodz, Poland
Beata Smolarz
Laboratory of Cancer Genetics, Department of Pathology, Polish Mother’s Memorial Hospital Research Institute, Rzgowska 281/289, 93-338 Lodz, Poland
Marzena Podhorska-Okołów
Division of Ultrastructure Research, Department of Human Morphology and Embryology, Wroclaw Medical University, T. Chalubinskiego 6a St., 50-368 Wroclaw, Poland
Jędrzej Grzegrzółka
Division of Histology and Embryology, Department of Human Morphology and Embryology, Wroclaw Medical University, T. Chalubinskiego 6a St., 50-368 Wroclaw, Poland
Agnieszka Rusak
Division of Histology and Embryology, Department of Human Morphology and Embryology, Wroclaw Medical University, T. Chalubinskiego 6a St., 50-368 Wroclaw, Poland
Piotr Dzięgiel
Division of Histology and Embryology, Department of Human Morphology and Embryology, Wroclaw Medical University, T. Chalubinskiego 6a St., 50-368 Wroclaw, Poland
Epithelial-to-mesenchymal transition (EMT) is a complex cellular process that allows cells to change their phenotype from epithelial to mesenchymal-like. Type 3 EMT occurs during cancer progression. The aim of this study was to investigate the role of RNA-binding motif single-stranded interacting protein 3 (RBMS 3) in the process of EMT. To investigate the impact of RBMS 3 on EMT, we performed immunohistochemical (IHC) reactions on archived paraffin blocks of invasive ductal breast carcinoma (n = 449), allowing us to analyze the correlation in expression between RBMS 3 and common markers of EMT. The IHC results confirmed the association of RBMS 3 with EMT markers. Furthermore, we performed an in vitro study using cellular models of triple negative and HER-2-enriched breast cancer with the overexpression and silencing of RBMS 3. RT-qPCR and Western blot methods were used to detect changes at both the mRNA and protein levels. An invasion assay and confocal microscopy were used to study the migratory potential of cells depending on the RBMS 3 expression. The studies conducted suggest that RBMS 3 may potentially act as an EMT-promoting agent in the most aggressive subtype of breast cancer, triple negative breast cancer (TNBC), but as an EMT suppressor in the HER-2-enriched subtype. The results of this study indicate the complex role of RBMS 3 in regulating the EMT process and present it as a future potential target for personalized therapies and a diagnostic marker in breast cancer.
